Emyria Limited (ASX: EMD) reports strong 6-month outcomes for patients with treatment-resistant PTSD, including significant symptom improvement and durable treatment effects. With 63% of patients no longer meeting PTSD criteria and achieving quality-of-life scores comparable to the general population, Emyria's real-world program demonstrates meaningful and sustained improvements. These results, presented by Emyria's Chief Scientific Officer at Psychedelic Science 2025, emphasize the effectiveness of the Company's care model in providing lasting relief and quality of life gains.

The program's momentum continues with over 30 enrolled patients, highlighting scalability and increased demand for Emyria's care models. The Company's unique approach, which integrates psychotherapy, medications, and clinical oversight, delivers durable benefits in a real-world setting for individuals who have not responded to standard treatments. Emyria's data-driven model positions it as a trusted partner for insurers and government agencies, with active discussions to secure funding agreements for expanding access to care programs.

Furthermore, Emyria's strategic partnership with ANU aims to strengthen research and clinical validation, collaborating on evidence-based protocols and professional development frameworks. This collaboration underscores Emyria's leadership in frontline care delivery and real-world data generation, paving the way for advanced treatments in mental health. For more information or investment opportunities, please contact Greg Hutchinson, Executive Chair, at +61 (0) 8 6559 2800 or ghutchinson@emyria.com. Investors are encouraged to engage with Emyria through the Investor Hub for interactive updates and inquiries.

Please note the risks associated with the use of MDMA, MDMA-inspired compounds, and psilocybin, which require specialist assessment and monitoring for adverse effects during treatment. Emyria continues to advance its therapies and drug development programs, with a commitment to transparency and ongoing evaluation of its products.